[{"address1": "300 Boston Scientific Way", "city": "Marlborough", "state": "MA", "zip": "01752-1234", "country": "United States", "phone": "508 683 4000", "website": "https://www.bostonscientific.com", "industry": "Medical Devices", "industryKey": "medical-devices", "industryDisp": "Medical Devices", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.", "fullTimeEmployees": 48000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael F. Mahoney", "age": 58, "title": "Chairman, President & CEO", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 4834331, "exercisedValue": 12979359, "unexercisedValue": 48750128}, {"maxAge": 1, "name": "Mr. Daniel J. Brennan", "age": 57, "title": "Executive VP & CFO", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 2149143, "exercisedValue": 1712363, "unexercisedValue": 9815151}, {"maxAge": 1, "name": "Mr. Joseph M. Fitzgerald", "age": 59, "title": "Executive VP & Group President of Cardiology", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 1837589, "exercisedValue": 4703150, "unexercisedValue": 20995452}, {"maxAge": 1, "name": "Mr. Jeffrey B. Mirviss M.B.A.", "age": 57, "title": "Executive VP & President of Peripheral Interventions", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1438566, "exercisedValue": 0, "unexercisedValue": 6903812}, {"maxAge": 1, "name": "Mr. Arthur Crosswell  Butcher", "age": 52, "title": "Executive VP and Group President of MedSurg & Asia Pacific", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1491248, "exercisedValue": 626042, "unexercisedValue": 4262597}, {"maxAge": 1, "name": "Mr. John Bradley Sorenson", "age": 55, "title": "Executive Vice President of Global Operations", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  Woodworth", "age": 45, "title": "Senior VP, Global Controller & Chief Accounting Officer", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jodi Euerle Eddy", "age": 49, "title": "Senior VP and Chief Information & Digital Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan R Monson", "title": "Senior VP of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vance R. Brown", "age": 53, "title": "Senior VP, General Counsel & Corporate Secretary", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 4, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://phx.corporate-ir.net/phoenix.zhtml?c=62272&p=irol-irhome", "maxAge": 86400, "priceHint": 2, "previousClose": 81.96, "open": 81.77, "dayLow": 80.5, "dayHigh": 81.88, "regularMarketPreviousClose": 81.96, "regularMarketOpen": 81.77, "regularMarketDayLow": 80.5, "regularMarketDayHigh": 81.88, "beta": 0.797, "trailingPE": 66.15447, "forwardPE": 29.805862, "volume": 4459665, "regularMarketVolume": 4459665, "averageVolume": 5545338, "averageVolume10days": 4466930, "averageDailyVolume10Day": 4466930, "bid": 80.94, "ask": 81.01, "bidSize": 1000, "askSize": 1000, "marketCap": 119827906560, "fiftyTwoWeekLow": 48.35, "fiftyTwoWeekHigh": 82.47, "priceToSalesTrailing12Months": 7.868403, "fiftyDayAverage": 77.1498, "twoHundredDayAverage": 68.74185, "currency": "USD", "enterpriseValue": 128957440000, "profitMargins": 0.119969994, "floatShares": 1468149352, "sharesOutstanding": 1472630016, "sharesShort": 10743082, "sharesShortPriorMonth": 11525968, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0073, "heldPercentInsiders": 0.0018799999, "heldPercentInstitutions": 0.92866, "shortRatio": 1.61, "shortPercentOfFloat": 0.0073, "impliedSharesOutstanding": 1472630016, "bookValue": 13.848, "priceToBook": 5.8759394, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 0.2, "netIncomeToCommon": 1828000000, "trailingEps": 1.23, "forwardEps": 2.73, "pegRatio": 2.65, "lastSplitFactor": "2:1", "lastSplitDate": 1068076800, "enterpriseToRevenue": 8.468, "enterpriseToEbitda": 32.664, "52WeekChange": 0.5208758, "SandP52WeekChange": 0.24014747, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "BSX", "underlyingSymbol": "BSX", "shortName": "Boston Scientific Corporation", "longName": "Boston Scientific Corporation", "firstTradeDateEpochUtc": 706282200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "69b49f65-05eb-36c8-ab80-d5db1263e17a", "messageBoardId": "finmb_317627", "gmtOffSetMilliseconds": -14400000, "currentPrice": 81.37, "targetHighPrice": 100.0, "targetLowPrice": 78.0, "targetMeanPrice": 87.94, "targetMedianPrice": 87.5, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 30, "totalCash": 2912999936, "totalCashPerShare": 1.978, "ebitda": 3948000000, "totalDebt": 10936000512, "quickRatio": 0.953, "currentRatio": 1.612, "totalRevenue": 15228999680, "debtToEquity": 53.064, "revenuePerShare": 10.379, "returnOnAssets": 0.04808, "returnOnEquity": 0.093210004, "freeCashflow": 1611500032, "operatingCashflow": 2632000000, "earningsGrowth": 0.222, "revenueGrowth": 0.145, "grossMargins": 0.68691003, "ebitdaMargins": 0.25924, "operatingMargins": 0.19393, "financialCurrency": "USD", "trailingPegRatio": 2.0169, "__fetch_time": "2024-09-05"}]